Moneycontrol PRO

Buy Divi's Laboratories; target of Rs 4425: ICICI Direct

ICICI Securities is bullish on Divi's Laboratories recommended buy rating on the stock with a target price of Rs 4425 in its research report dated December 30, 2020.

December 30, 2020 / 12:42 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Divi's Laboratories

Revenues grew 33.4% YoY to Rs 3480 crore in H1FY21. Generic segment grew 38.6% YoY to Rs 1777 crore. Custom synthesis grew 31.8% YoY to Rs 1409 crore. Carotenoids grew 14.0% YoY to Rs 294 crore. EBITDA margins expanded 777 bps YoY to 41.4% due to significantly better gross margin performance and lower other expenditure. Subsequently, EBITDA grew 64.2% YoY to Rs 1441 crore. Net profit grew 60.8% YoY to Rs 1012 crore in-line with a strong operational performance.


We maintain BUY with a target price of Rs 4425 based on 40x FY23E EPS of Rs 110.6.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Dec 30, 2020 12:42 pm
ISO 27001 - BSI Assurance Mark